According to the news on November 20th from Guizhou Internet Radio and Television Station, the Xinfeng police in Ganzhou, Jiangxi recently successfully cracked a case involving the use of methyl ethyl ketone to produce "Shangtou e-cigarettes". In total, seven suspects involved in illegal activities were arrested.
According to data from the police, the urine test results of arrested suspects have all shown positive for eutylone. On the other hand, cases related to eutylone have also been successively cracked in Xishui, Hubei and Yuncheng, Guangdong, once again highlighting the dangers of eutylone in the illegal market.
Dependence on Etomidate", known as a type of prescription anesthetic, can only be legally used by medical institutions that have obtained a "Pharmaceutical Business License." Similarly, only pharmaceutical wholesale and retail enterprises with a "Pharmaceutical Business License" can sell raw materials and preparations of "Etomidate.
In September of this year, the National Medical Products Administration, Ministry of Public Security, and National Health Commission issued a public announcement regarding the adjustment of the catalogue of anesthetic and psychotropic drugs. It states that methylphenidate will be included in the second category of the psychotropic drug catalogue, excluding drugs containing methylphenidate that have been approved for sale within China. This adjustment will take effect from October 1, 2023.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
